Triazole-containing Heterocycles: Privileged Scaffolds in Anti-Trypanosoma
Cruzi Drug Development

Kamdem    Boniface    Pone; Sadou       Dalhatou; Hugues    Kamdem    Paumo; Lebogang    Maureen    Katata-Seru; Elizabeth    Igne    Ferreira
Abstract

Background: Chagas disease is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi and is transmitted to humans through the excreta of infected blood-sucking triatomine bugs. According to the World Health Organization, 6 to 7 million people are infected with T. cruzi worldwide, mainly in Latin America, with more than 10000 deaths annually.
Aim of the Study: The present study aims to provide comprehensive literature information on the importance of triazole-containing heterocycles in developing anti-Chagas disease agents.
Methodology: The embodied information was acquired without date limitation by December 2020 using various electronic databases including, SciFinder, PubMed (National Library of Medicine), Science Direct, Wiley, ACS (American Chemical Society), SciELO (Scientific Electronic Library Online), Google Scholar, Springer, Scopus, and Web of Science.
Results: Upon in vitro studies, more than 100 triazole-containing heterocycles have been predicted as active compounds against the pathogen responsible for the American trypanosomiasis. However, less is known about their in vivo activity in animal models and their clinical studies in humans. Moreover, the pharmacokinetic studies of these bioactive compounds are still pending. Despite the variety of mechanisms of action attributed to most of these molecules, the exact mechanism involved is still controversial. Thus, in vivo experiments, followed by pharmacokinetics, and the mechanism of action of the most active compounds, should be the subject of future investigation.
Conclusion: All in all, recent studies have demonstrated the importance of triazole-containing heterocycles in search of potential candidates for drug development against Chagas disease. Nonetheless, the use of new catalysts and chemical transformations is expected to provide avenues for the synthesis of unexplored triazole derivatives, leading to the development of triazole-containing compounds with new properties and trypanocidal activity.
Keywords: Triazoles, american trypanosomiasis, protozoan parasite, synthesis, drug discovery, neglected disease.
Graphical Abstract

[1] 
Ribeiro V, Dias N, Paiva T, et al. Current trends in the pharmacological management of Chagas disease. Int J Parasitol Drugs Drug Resist  2020; 12: 7-17.
[http://dx.doi.org/10.1016/j.ijpddr.2019.11.004] [PMID: 31862616] 
[2] 
WHO (World Health Organization). Health topics.  Chagas disease (American Trypanosomiasis) The fact sheets 2020. Available at:
          https://www.who.int/health-topics/chagas-disease#tab=tab_2 [Assessed on 30th November 2020].
[3] 
Bocchi EA, Bestetti RB, Scanavacca MI, Neto EC, Issa VS. J Am Coll Cardiol  2017; 70: 1511-24.
[http://dx.doi.org/10.1016/j.jacc.2017.08.004] 
[4] 
Pérez-Molina JA, Molina I. Chagas disease cardiomyopathy treatment remains a challenge - Authors’ reply. Lancet  2018; 391(10136): 2209-10.
[http://dx.doi.org/10.1016/S0140-6736(18)30776-1] [PMID: 29893217] 
[5] 
Boniface PK, Ferreira EI. Flavonoids as efficient scaffolds: Recent trends for malaria, leishmaniasis, Chagas disease, and dengue. Phytother Res  2019; 33(10): 2473-517.
[http://dx.doi.org/10.1002/ptr.6383] [PMID: 31441148] 
[6] 
Beltran-Hortelano I, Alcolea V, Font M, Pérez-Silanes S. The role of imidazole and benzimidazole heterocycles in Chagas disease: A review. Eur J Med Chem  2020; 206: 112692.
[http://dx.doi.org/10.1016/j.ejmech.2020.112692] [PMID: 32818869] 
[7] 
DNDi (Drug for Neglected Diseases Initiative) 2020. Available at:
          https://dndi.org/diseases/chagas/facts/Accessed on 14th October 2020
[8] 
Haider S, Alam MS, Hamid H. 1,2,3-Triazoles: scaffold with medicinal significance. Inflamm Cell Signal  2014; 1: e95.
[9] 
Costa AV, Moreira LC, Pinto RT, et al. Synthesis of glycerol-derived 4-alkyl-substituted 1,2,3-triazoles and evaluation of their fungicidal, phytotoxic, and antiproliferative activities. J Braz Chem Soc  2020; 31: 821-32.
[http://dx.doi.org/10.21577/0103-5053.20190246] 
[10] 
Ram VJ, Sethi A, Nath M, Pratap R. The chemistry of heterocycles. Nomenclature of three-to-five membered heterocycles.  Chapter 5-Five Membered Heterocycles  2019; 149-478.
[11] 
Aggarwal R, Sumran G. An insight on medicinal attributes of 1,2,4-triazoles. Eur J Med Chem  2020; 205: 112652.
[http://dx.doi.org/10.1016/j.ejmech.2020.112652] [PMID: 32771798] 
[12] 
Campo VL, Sesti-Costa R, Carneiro ZA, Silva JS, Schenkman S, Carvalho I. Design, synthesis and the effect of 1,2,3-triazole sialylmimetic neoglycoconjugates on Trypanosoma cruzi and its cell surface trans-sialidase. Bioorg Med Chem  2012; 20(1): 145-56.
[http://dx.doi.org/10.1016/j.bmc.2011.11.022] [PMID: 22154559] 
[13] 
de Andrade P, Galo OA, Carvalho MR, et al. 1,2,3-Triazole-based analogue of benznidazole displays remarkable activity against Trypanosoma cruzi. Bioorg Med Chem  2015; 23(21): 6815-26.
[http://dx.doi.org/10.1016/j.bmc.2015.10.008] [PMID: 26476667] 
[14] 
Chaves-Mello F, do V, Quaresma BMS, et al. Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities. Bioorg Med Chem  2017; 25: 6049-59.
[15] 
Brand S, Ko EJ, Viayna E, et al. Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi. J Med Chem  2017; 60(17): 7284-99.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00463] [PMID: 28844141] 
[16] 
Pertino MW, F de la Torre A, Schmeda-Hirschmann G, et al. Synthesis, trypanocidal and anti-leishmania activity of new triazole-lapachol and nor-lapachol hybrids. Bioorg Chem  2020; 103: 104122.
[http://dx.doi.org/10.1016/j.bioorg.2020.104122] [PMID: 32745754] 
[17] 
Franklim TN, Freire-de-Lima L, de Nazareth Sá Diniz J, et al. Design, synthesis and trypanocidal evaluation of novel 1,2,4-triazoles-3-thiones derived from natural piperine. Molecules  2013; 18(6): 6366-82.
[http://dx.doi.org/10.3390/molecules18066366] [PMID: 23760033] 
[18] 
Papadopoulou MV, Bloomer WD, Rosenzweig HS, Kaiser M, Chatelain E, Ioset JR. Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents. Bioorg Med Chem  2013; 21(21): 6600-7.
[http://dx.doi.org/10.1016/j.bmc.2013.08.022] [PMID: 24012457] 
[19] 
Papadopoulou MV, Bloomer WD, Rosenzweig HS, Wilkinson SR, Kaiser M. Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. Eur J Med Chem  2014; 87: 79-88.
[http://dx.doi.org/10.1016/j.ejmech.2014.09.045] [PMID: 25240098] 
[20] 
Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation. Bioorg Med Chem  2015; 23(19): 6467-76.
[http://dx.doi.org/10.1016/j.bmc.2015.08.014] [PMID: 26344593] 
[21] 
Papadopoulou MV, Bloomer WD, Rosenzweig HS, Wilkinson SR, Szular J, Kaiser M. Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity. Eur J Med Chem  2016; 123: 895-904.
[http://dx.doi.org/10.1016/j.ejmech.2016.08.002] [PMID: 27543881] 
[22] 
Papadopoulou MV, Bloomer WD, Rosenzweig HS, Kaiser M. The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines. Eur J Med Chem  2017; 138: 1106-13.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.060] [PMID: 28763645] 
[23] 
Souza ROMA, Miranda LSME. Strategies Towards the synthesis of N-2 substituted 1,2,3-triazoles. An Acad Bras Cienc  2019; 91(Suppl. 1): e20180751.
[http://dx.doi.org/10.1590/0001-3765201820180751] [PMID: 30785471] 
[24] 
Maddila S, Pagadala R, Jonnalagadda SB. 1,2,4-Triazoles: A review of synthetic approaches and the biological activity. Lett Org Chem  2013; 10: 693-714.
[http://dx.doi.org/10.2174/157017861010131126115448] 
[25] 
Al-Masoudi IA, Al-Soud YA, Al-Salihi NJ, Al-Masoudi NA. 1,2,4-Triazoles: synthetic approaches and pharmacological importance. Chem Heterocycl Compd  2006; 42(11): 1377-403.
[http://dx.doi.org/10.1007/s10593-006-0255-3] 
[26] 
Tornøe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem  2002; 67(9): 3057-64.
[http://dx.doi.org/10.1021/jo011148j] [PMID: 11975567] 
[27] 
Haldón E, Nicasio MC, Pérez PJ. Copper-catalysed azide-alkyne cycloadditions (CuAAC): an update. Org Biomol Chem  2015; 13(37): 9528-50.
[http://dx.doi.org/10.1039/C5OB01457C] [PMID: 26284434] 
[28] 
Huisgen R. 1,3-Dipolar cycloadditions. Proceedings of the Chemical Society.  357.
[29] 
Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew Chem Int Ed Engl  2002; 41(14): 2596-9.
[http://dx.doi.org/10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4] [PMID: 12203546] 
[30] 
Kolb HC, Finn MG, Sharpless KB. Click chemistry: Diverse chemical function from a few good reactions. Angew Chem Int Ed Engl  2001; 40(11): 2004-21.
[http://dx.doi.org/10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5] [PMID: 11433435] 
[31] 
Zhou Z, Li S, Zhang Y, Liu M, Li W. Promotion of proton conduction in polymer electrolyte membranes by 1H-1,2,3-triazole. J Am Chem Soc  2005; 127(31): 10824-5.
[http://dx.doi.org/10.1021/ja052280u] [PMID: 16076176] 
[32] 
Li YC, Qi C, Li SH, et al. 1,1′-Azobis-1,2,3-triazole: a high-nitrogen compound with stable N8 structure and photochromism. J Am Chem Soc  2010; 132(35): 12172-3.
[http://dx.doi.org/10.1021/ja103525v] [PMID: 20715773] 
[33] 
Boechat N, Ferreira VF, Ferreira SB, et al. Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain. J Med Chem  2011; 54(17): 5988-99.
[http://dx.doi.org/10.1021/jm2003624] [PMID: 21776985] 
[34] 
Dheer D, Singh V, Shankar R. Medicinal attributes of 1,2,3-triazoles: Current developments. Bioorg Chem  2017; 71: 30-54.
[http://dx.doi.org/10.1016/j.bioorg.2017.01.010] [PMID: 28126288] 
[35] 
Zhang S, Xu Z, Gao C, et al. Triazole derivatives and their anti-tubercular activity. Eur J Med Chem  2017; 138: 501-13.
[http://dx.doi.org/10.1016/j.ejmech.2017.06.051] [PMID: 28692915] 
[36] 
Agard NJ, Prescher JA, Bertozzi CRA. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. J Am Chem Soc  2004; 126(46): 15046-7.
[http://dx.doi.org/10.1021/ja044996f] [PMID: 15547999] 
[37] 
Wang Q, Chan TR, Hilgraf R, Fokin VV, Sharpless KB, Finn MG. Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc  2003; 125(11): 3192-3.
[http://dx.doi.org/10.1021/ja021381e] [PMID: 12630856] 
[38] 
Ramachary DB, Ramakumar K, Narayana VV. Amino acid-catalyzed cascade [3+2]-cycloaddition/hydrolysis reactions based on the push-pull dienamine platform: synthesis of highly functionalized NH-1,2,3-triazoles. Chemistry  2008; 14(30): 9143-7.
[http://dx.doi.org/10.1002/chem.200801325] [PMID: 18767077] 
[39] 
Li H, Aneja R, Chaiken I. Click chemistry in peptide-based drug design. Molecules  2013; 18(8): 9797-817.
[http://dx.doi.org/10.3390/molecules18089797] [PMID: 23959192] 
[40] 
Boulton AJ, Katritzky AR. N-Oxides and related compounds. Part XXII. The rearrangement of 4-nitrobenzofuroxans to 7-nitrobenzofuroxans. Rev Roum Chim  1962; 7: 691-7.
[41] 
Boulton AJ, Ghosh PB, Katritzky AR. Heterocyclic rearrangements. Part V. Rearrangement of 4-arylazo-and 4-nitroso-benzofuroxans: New syntheses of the benzotriazole and benzofurazan ring systems.  J Chem Soc B Phys Org  1966; 1004-11.
[42] 
Stollè R. Über die konstitution der osotetrazine und amino-osotriazole.  Berichte der deutschen chemischen gesellschaft (A and B Series)  1926; 59: 1742-7.
[43] 
Hegarty AF, Quain P, O’Mahony TAF, Scott FL. Mechanism of cyclisation of N-(1,2,4-triazol3-yl)hydrazonyl bromides to mixtures of isomeric triazolo triazoles. J Chem Soc  1974; 2: 997-1004.
[44] 
Guru MM, Punniyamurthy T. Copper(II)-catalyzed aerobic oxidative synthesis of substituted 1,2,3- and 1,2,4-triazoles from bisarylhydrazones via C-H functionalization/C-C/N-N/C-N bonds formation. J Org Chem  2012; 77(11): 5063-73.
[http://dx.doi.org/10.1021/jo300592t] [PMID: 22571669] 
[45] 
Zhu C, Zeng H, Chen F, et al. Copper-catalyzed coupling of oxime acetates and aryldiazonium salts: An azide-free strategy toward N-2-aryl-1,2,3-triazoles. Org Chem Front  2018; 5: 571-6.
[http://dx.doi.org/10.1039/C7QO00874K] 
[46] 
Kseniya GD, Lesogorova SG, Sukhorukova ES, et al. Synthesis of 2-aryl-1,2,3-triazoles by oxidative cyclization of 2-(arylazo)ethene-1,1- diamines: a one-pot approach. Eur J Org Chem  2016; 2016(11): 2700-10.
[47] 
Watanabe T, Umezawa Y, Takahashi Y, Akamatsu Y. Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors. Bioorg Med Chem Lett  2010; 20(19): 5807-10.
[http://dx.doi.org/10.1016/j.bmcl.2010.07.131] [PMID: 20728352] 
[48] 
Gonzaga D, Senger MR, da Silva FdeC, Ferreira VF, Silva FP Jr. 1-Phenyl-1H- and 2-phenyl-2H-1,2,3-triazol derivatives: design, synthesis and inhibitory effect on alpha-glycosidases. Eur J Med Chem  2014; 74: 461-76.
[http://dx.doi.org/10.1016/j.ejmech.2013.12.039] [PMID: 24487194] 
[49] 
Baxter CA, Cleator E, Brands KMJ, et al. The first large scale synthesis of MK-4305: a dual orexin receptor antagonist for the treatment of sleep disorder. Org Process Res Dev  2011; 15: 367-75.
[http://dx.doi.org/10.1021/op1002853] 
[50] 
Adibekian A, Martin BR, Wang C, et al. Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. Nat Chem Biol  2011; 7(7): 469-78.
[http://dx.doi.org/10.1038/nchembio.579] [PMID: 21572424] 
[51] 
Silva RA, Quintela ED, Mascarin GM, Barrigossi JAF, Lião LM. Compatibility of conventional agrochemicals used in rice crops with the entomopathogenic fungus Metarhizium anisopliae. Sci Agric  2013; 70: 152-60.
[http://dx.doi.org/10.1590/S0103-90162013000300003] 
[52] 
Desai PS, Indorwala NS. Triazoles used as a corrosion inhibitor for mild steel in hydrochloric acid. Int J Curr Microbiol Appl Sci  2015; 4: 928-38.
[53] 
McNeill KS, Cancilla DA. Detection of triazole deicing additives in soil samples from airports with low, mid, and large volume aircraft deicing activities. Bull Environ Contam Toxicol  2009; 82(3): 265-9.
[http://dx.doi.org/10.1007/s00128-008-9626-z] [PMID: 19082516] 
[54] 
Schulze B, Schubert US. Beyond click chemistry - supramolecular interactions of 1,2,3-triazoles. Chem Soc Rev  2014; 43(8): 2522-71.
[http://dx.doi.org/10.1039/c3cs60386e] [PMID: 24492745] 
[55] 
Arseneault M, Wafer C, Morin JF. Recent advances in click chemistry applied to dendrimer synthesis. Molecules  2015; 20(5): 9263-94.
[http://dx.doi.org/10.3390/molecules20059263] [PMID: 26007183] 
[56] 
Balamurugan S, Yeap GY, Mahmood WAK. Calamitic liquid crystals of 1,2,3-triazole connected to azobenzene: synthesis, characterisation and anisotropic properties. Liq Cryst  2014; 41: 776-83.
[http://dx.doi.org/10.1080/02678292.2014.889231] 
[57] 
Miladinova PM, Konstantinova TN. Photo stabilizers for polymers-new trends. J Chem Tech Metall  2015; 50: 229-39.
[58] 
Rajalekshmi KM, Jaleel CA, Azooz MM, Panneerselvam R. Effect of triazole growth regulators on growth and pigment contents in Plectranthus aromaticus and Plectranthus vettiveroides. Adv Biol Res (Faisalabad)  2009; 3: 117-22.
[59] 
Zhang G, Wang Y, Wen X, Ding C, Li Y. Dual-functional click-triazole: a metal chelator and immobilization linker for the construction of a heterogeneous palladium catalyst and its application for the aerobic oxidation of alcohols. Chem Commun (Camb)  2012; 48(24): 2979-81.
[http://dx.doi.org/10.1039/c2cc18023e] [PMID: 22331347] 
[60] 
El-Khawass SM, Habib NS. Synthesis of 1,2,4-triazole, 12,4-triazolo[3,4-b] [1,3,4] thiadiazole and 1,2,4-triazolo[3,4-b] [1,3,4] thiadiazine derivatives of benzotriazole. J Heterocycl Chem  1989; 26(1): 177-81.
[http://dx.doi.org/10.1002/jhet.5570260131] 
[61] 
Tarrago G, Marzin C, Najimi D, Pellegrin V. New tetra heterocyclic macrocycles containing triazole, pyrazole, pyridine, and/or furan subunits. Synthesis and cation-binding properties. J Org Chem  1990; 55(2): 420.
[http://dx.doi.org/10.1021/jo00289a008] 
[62] 
de Mendoza J, Ontoria JM, Ortega MC, Torres T. Synthesis of 3,5-biscarbonyl-1H-1,2,4-triazole derivatives. Synthesis  1992; 4: 398-402.
[http://dx.doi.org/10.1055/s-1992-26122] 
[63] 
Abdelhamdi AO, Mohamed MA, Zaki YH. Reactions with hydrazononoyl halides 591: Synthesis and antimicrobial activity of 2,3-dihydro-1,3,4-thiazole, triazolino[4,3-a] pyrimidine, and pyrimido[1,2-b] [1,2,4,5]tetrazin-6-one containing benzofuran moiety. Phosphorus Sulfur Silicon Relat Elem  2008; 183: 1746-54.
[http://dx.doi.org/10.1080/10426500701734265] 
[64] 
Bentiss F, Lagrenee M, Barby D. Accelerated synthesis of 3,5-disubstituted 4-amino-1,2,4-triazoles under microwave irradiation. Tetrahedron Lett  2000; 41: 1539-41.
[http://dx.doi.org/10.1016/S0040-4039(99)02350-3] 
[65] 
Rostamizadeh S, Tajik H, Yazdanfarahi S. Solid phase synthesis of 1,2,4-triazoles under microwave irradiation. Synth Commun  2003; 33(1): 113-7.
[http://dx.doi.org/10.1081/SCC-120015566] 
[66] 
Li D, Bao H, You T. Microwave-assisted and efficient one-pot synthesis of substituted 1,2,4-triazoles. Heterocycles  2005; 65(8): 1957-62.
[http://dx.doi.org/10.3987/COM-05-10415] 
[67] 
Polya JB. Comprehensive Heterocyclic Chemistry.  Headington Hill Hall, Oxford, England: Pergamon Press 1984; 5: p. 733.
[68] 
Lynn MK, Bossak BH, Sandifer PA, Watson A, Nolan MS. Contemporary autochthonous human Chagas disease in the USA. Acta Trop  2020; 205: 105361.
[http://dx.doi.org/10.1016/j.actatropica.2020.105361] [PMID: 32006523] 
[69] 
Stevens L, Dorn PL, Hobson J, et al. Vector blood meals and Chagas disease transmission potential, United States. Emerg Infect Dis  2012; 18(4): 646-9.
[http://dx.doi.org/10.3201/eid1804.111396] [PMID: 22469536] 
[70] 
Lidani KCF, Andrade FA, Bavia L, et al. Chagas disease: From discovery to a worldwide health problem.  Front Public Health  2019; 7(166): 13.
[71] 
Santos SS, de Araújo RV, Giarolla J, Seoud OE, Ferreira EI. Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review. Int J Antimicrob Agents  2020; 55(4): 105906.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105906] [PMID: 31987883] 
[72] 
Dias JCP. Elimination of Chagas disease transmission: perspectives. Mem Inst Oswaldo Cruz  2009; 104(Suppl. 1): 41-5.
[http://dx.doi.org/10.1590/S0074-02762009000900007] [PMID: 19753456] 
[73] 
Peterson JK, Hashimoto K, Yoshioka K, et al. Chagas disease in Central America: Recent findings and current challenges in vector ecology and control. Curr Trop Med Rep  2019; 6: 76-91.
[http://dx.doi.org/10.1007/s40475-019-00175-0] 
[74] 
da Silva EN Jr, Menna-Barreto RFS, Pinto MdoC, et al. Naphthoquinoidal [1,2,3]-triazole, a new structural moiety active against Trypanosoma cruzi. Eur J Med Chem  2008; 43(8): 1774-80.
[http://dx.doi.org/10.1016/j.ejmech.2007.10.015] [PMID: 18045742] 
[75] 
da Silva Júnior EN, de Melo IMM, Diogo EBT, et al. On the search for potential anti-Trypanosoma cruzi drugs: synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1,2,3-triazolic naphthoquinoidal compounds obtained by click chemistry reactions. Eur J Med Chem  2012; 52: 304-12.
[http://dx.doi.org/10.1016/j.ejmech.2012.03.039] [PMID: 22483633] 
[76] 
de Castro SL, Emery FS, da Silva Júnior EN. Synthesis of quinoidal molecules: strategies towards bioactive compounds with an emphasis on lapachones. Eur J Med Chem  2013; 69: 678-700.
[http://dx.doi.org/10.1016/j.ejmech.2013.07.057] [PMID: 24095760] 
[77] 
Diogo EBT, Dias GG, Rodrigues BL, et al. Synthesis and anti-Trypanosoma cruzi activity of naphthoquinone-containing triazoles: electrochemical studies on the effects of the quinoidal moiety. Bioorg Med Chem  2013; 21(21): 6337-48.
[http://dx.doi.org/10.1016/j.bmc.2013.08.055] [PMID: 24074878] 
[78] 
Verduzco-Ramirez A, Manzanilla-Davila S, Morales-Guillen ME, et al. Essential metal-based drugs: Correlation between redox potential and biological activity of M2+ with a N2O2 ligand. J Mex Chem Soc  2017; 61(2): 109-19.
[http://dx.doi.org/10.29356/jmcs.v61i2.258] 
[79] 
Polak A, Richle R. Mode of action of the 2-nitroimidazole derivative benznidazole. Ann Trop Med Parasitol  1978; 72(1): 45-54.
[http://dx.doi.org/10.1080/00034983.1978.11719278] [PMID: 418744] 
[80] 
Soy D, Aldasoro E, Guerrero L, et al. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother  2015; 59(6): 3342-9.
[http://dx.doi.org/10.1128/AAC.05018-14] [PMID: 25824212] 
[81] 
Coronel MVP, Frutos LO, Muñoz EC, Valle DK, Rojas DH. Adverse systemic reaction to benznidazole. Rev Soc Bras Med Trop  2017; 50(1): 145-7.
[http://dx.doi.org/10.1590/0037-8682-0071-2016] [PMID: 28327820] 
[82] 
Rajão MA, Furtado C, Alves CL, et al. Unveiling benznidazole’s mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. Environ Mol Mutagen  2014; 55(4): 309-21.
[http://dx.doi.org/10.1002/em.21839] [PMID: 24347026] 
[83] 
Cirqueira ML. Structural studies on Trypanosoma cruzi nitroreductase enzyme: characterization of prodrug activation mechanism for benznidazole and nifurtimox.  Dissertation (Master)  2019; 75.
[84] 
Marchiori MF, Riul TB, Oliveira Bortot L, et al. Binding of triazole-linked galactosyl arylsulfonamides to galectin-3 affects Trypanosoma cruzi cell invasion. Bioorg Med Chem  2017; 25(21): 6049-59.
[http://dx.doi.org/10.1016/j.bmc.2017.09.042] [PMID: 29032929] 
[85] 
Zacchi CHC, Federighi SSM, Gadelha FR, Martins FT, Alves RB, de Fatima A. Synthesis of potential anti-Trypanosoma cruzi azole-naftifine analogues by azide-alkyne click reaction. Mendeleev Commun  2018; 28: 195-7.
[http://dx.doi.org/10.1016/j.mencom.2018.03.029] 
[86] 
Pasko MT, Piscitelli SC, Van Slooten AD. Fluconazole: a new triazole antifungal agent. DICP  1990; 24(9): 860-7.
[http://dx.doi.org/10.1177/106002809002400914] [PMID: 2260347] 
[87] 
Zimmermann LA, de Moraes MH, da Rosa R, et al. Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity. Bioorg Med Chem  2018; 26(17): 4850-62.
[http://dx.doi.org/10.1016/j.bmc.2018.08.025] [PMID: 30173929] 
[88] 
Urbina JA, Lira R, Visbal G, Bartrolí J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother  2000; 44(9): 2498-502.
[http://dx.doi.org/10.1128/AAC.44.9.2498-2502.2000] [PMID: 10952601] 
[89] 
Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents  2003; 21(1): 27-38.
[http://dx.doi.org/10.1016/S0924-8579(02)00273-X] [PMID: 12507835] 
[90] 
Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz  2009; 104(Suppl. 1): 311-8.
[http://dx.doi.org/10.1590/S0074-02762009000900041] [PMID: 19753490] 
[91] 
Girault S, Grellier P, Berecibar A, et al. Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker. J Med Chem  2000; 43(14): 2646-54.
[http://dx.doi.org/10.1021/jm990946n] [PMID: 10893302] 
[92] 
Silva FT, Franco CH, Favaro DC, Freitas-Junior LH, Moraes CB, Ferreira EI. Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues. Eur J Med Chem  2016; 121: 553-60.
[http://dx.doi.org/10.1016/j.ejmech.2016.04.065] [PMID: 27318979] 
[93] 
Thompson AM, O’Connor PD, Marshall AJ, et al. Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. Eur J Med Chem  2020; 207: 112849.
[http://dx.doi.org/10.1016/j.ejmech.2020.112849] [PMID: 33007723] 
[94] 
Bennani YL. Drug discovery in the next decade: innovation needed ASAP. Drug Discov Today  2011; 16(17-18): 779-92.
[http://dx.doi.org/10.1016/j.drudis.2011.06.004] [PMID: 21704185] 
[95] 
Freire-de-Lima L, Fonseca LM, Oeltmann T, Mendonça-Previato L, Previato JO. The trans-sialidase, the major Trypanosoma cruzi virulence factor: Three decades of studies. Glycobiology  2015; 25(11): 1142-9.
[http://dx.doi.org/10.1093/glycob/cwv057] [PMID: 26224786] 
[96] 
Buschiazzo A, Muiá R, Larrieux N, Pitcovsky T, Mucci J, Campetella O. Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: structure/function studies towards the rational design of inhibitors. PLoS Pathog  2012; 8(1): e1002474.
[http://dx.doi.org/10.1371/journal.ppat.1002474] [PMID: 22241998] 
[97] 
Morrone-Pozzuto P, Uhrig ML, Agusti R. Trypanosoma cruzi trans-sialidase alternative substrates: Study of the effect of substitution in C-6 in benzyl β-lactoside. Carbohydr Res  2019; 478: 33-45.
[http://dx.doi.org/10.1016/j.carres.2019.04.003] [PMID: 31054381] 
[98] 
dC-Rubin, S.S.C.; Schenkman, S. Trypanosoma cruzi trans-sialidase as a multifunctional enzyme in Chagas’ disease. Cell Microbiol  2012; 14(10): 1522-30.
[http://dx.doi.org/10.1111/j.1462-5822.2012.01831.x] [PMID: 22747789] 
[99] 
Carvalho ST, Sola-Penna M, Oliveira IA, et al. A new class of mechanism-based inhibitors for Trypanosoma cruzi trans-sialidase and their influence on parasite virulence. Glycobiology  2010; 20(8): 1034-45.
[http://dx.doi.org/10.1093/glycob/cwq065] [PMID: 20466651] 
[100] 
Maya JD, Cassels BK, Iturriaga-Vásquez P, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol  2007; 146(4): 601-20.
[http://dx.doi.org/10.1016/j.cbpa.2006.03.004] [PMID: 16626984] 
[101] 
Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA  2008; 105(13): 5022-7.
[http://dx.doi.org/10.1073/pnas.0711014105] [PMID: 18367671] 
[102] 
Jose Cazzulo J, Stoka V, Turk V. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr Pharm Des  2001; 7(12): 1143-56.
[http://dx.doi.org/10.2174/1381612013397528] [PMID: 11472258] 
[103] 
Scarim CB, Jornada DH, Chelucci RC, de Almeida L, Dos Santos JL, Chung MC. Current advances in drug discovery for Chagas disease. Eur J Med Chem  2018; 155: 824-38.
[http://dx.doi.org/10.1016/j.ejmech.2018.06.040] [PMID: 30033393] 
[104] 
de Oliveira C, Santana LA, Carmona AK, et al. Structure of cruzipain/cruzain inhibitors isolated from Bauhinia bauhinioides seeds. Biol Chem  2001; 382(5): 847-52.
[http://dx.doi.org/10.1515/bchm.2001.382.5.847] [PMID: 11517940] 
[105] 
Brak K, Doyle PS, McKerrow JH, Ellman JA. Identification of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc  2008; 130(20): 6404-10.
[http://dx.doi.org/10.1021/ja710254m] [PMID: 18435536] 
[106] 
Rocha DA, Silva EB, Fortes IS, Lopes MS, Ferreira RS, Andrade SF. Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors. Eur J Med Chem  2018; 157: 1426-59.
[http://dx.doi.org/10.1016/j.ejmech.2018.08.079] [PMID: 30282318] 
[107] 
Vázquez K, Paulino M, Salas CO, Zarate-Ramos JJ, Vera B, Rivera G. Trypanothione reductase: A target for the development of anti-Trypanosoma cruzi drugs. Mini Rev Med Chem  2017; 17(11): 939-46.
[http://dx.doi.org/10.2174/1389557517666170315145410] [PMID: 28302040] 
[108] 
Battista T, Colotti G, Ilari A, Fiorillo A. Targeting trypanothione reductase, a key enzyme in the redox trypanosomatid metabolism, to develop new drugs against leishmaniasis and trypanosomiases. Molecules  2020; 25(8): 1-17.
[http://dx.doi.org/10.3390/molecules25081924] [PMID: 32326257] 
[109] 
Kumar S, Ali MR, Bawa S. Mini review on tricyclic compounds as an inhibitor of trypanothione reductase. J Pharm Bioallied Sci  2014; 6(4): 222-8.
[http://dx.doi.org/10.4103/0975-7406.142943] [PMID: 25400403] 
[110] 
Cuevas-Hernández RI, Girard RMBM, Martínez-Cerón S, et al. A fluorinated phenylbenzothiazole arrests the Trypanosoma cruzi cell cycle and diminishes the infection of mammalian host cells. Antimicrob Agents Chemother  2020; 64(2): 1-16.
[PMID: 31712204] 
[111] 
Taylor D. The pharmaceutical industry and the future of drug development.Pharmaceuticals in the Environment.  Issues in Environmental Science and Technology 2015; pp. 1-33.
[http://dx.doi.org/10.1039/9781782622345-00001] 
[112] 
Ghaemi R, Selvaganapathy PR. Microfluidic devices for automation of assays on Drosophila melanogaster for applications in drug discovery and biological studies. Curr Pharm Biotechnol  2016; 17(9): 822-36.
[http://dx.doi.org/10.2174/1389201017666160519112506] [PMID: 27194358] 
[113] 
Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide-identification of problems obstacles. Transl Med Commun  2019; 4(18): 1-19.
[http://dx.doi.org/10.1186/s41231-019-0050-7] 
[114] 
Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol  2012; 6(2): 155-76.
[http://dx.doi.org/10.1016/j.molonc.2012.02.004] [PMID: 22440008] 
[115] 
Roy A. Challenges with risk mitigation in academic drug discovery: finding the best solution. Expert Opin Drug Discov  2019; 14(2): 95-100.
[http://dx.doi.org/10.1080/17460441.2019.1553952] [PMID: 30513005] 
[116] 
Kiriiri GK, Njogu PM, Mwangi AN. Exploring different approaches to improve the success of drug discovery and development projects: a review. Future J Pharm Sci  2020; 6(27): 1-12.
Cite As
Current Drug Targets

Triazole-containing Heterocycles: Privileged Scaffolds in Anti-Trypanosoma Cruzi Drug Development

Abstract

Graphical Abstract
